This study identifies a pronounced intention–implementation gap in AD biomarker use within a real-world Latin American setting. Despite broad acceptance and perceived clinical value, adoption remains limited by restricted therapeutic access, diagnostic availability, and clinician-level expertise. These findings suggest that successful global implementation of AD biomarkers will require parallel advances in access, education, and health system readiness, beyond biomarker development alone.